For personal use only

ASX Release **5 November 2025**

$6.1m in new funding raised to accelerate clinical development of TRP-8803 (IV-infused psilocin)

- **Firm commitments to raise $6.1m through the issue of 179,411,764 shares at $0.034 per share**
- **Strong support from existing investors including Tryp's co-founder and largest shareholder, Dr William Garner who has committed $572,000**
- **Existing Board, including Mr Herwig Janssen, Mr Jason Carroll, Dr Daniel Tillett, and Mr Chris Ntoumenopoulos have collectively committed a further $470,000 (subject to shareholder approval)**
- **Funds to fast track the world-first clinical trial with Swinburne University using TRP-8803 for the treatment of Binge Eating Disorder and to support additional clinical trials in other high value neuropsychiatric indications**
- **Funding will advance TRP-8803's drug manufacturing and regulatory engagement programs**

Melbourne, Australia – Tryptamine Therapeutics Limited ('**Tryp**', '**TYP**' or the '**Company**') (**ASX: TYP**), a clinical-stage biotechnology company, is pleased to advise it has secured firm commitments from sophisticated, professional and institutional investors to raise $6,100,000 through the issue of approximately 179,411,764 new fully paid ordinary shares ('Shares') at an issue price of $0.034 per Share ('Placement').

The Placement received strong support from both new and existing investors, including the Company's co-founder and largest shareholder, Dr William Garner who has committed $572,000. In addition, the existing Board members including Mr Herwig Janssen, Mr Jason Carroll, Dr Daniel Tillett, and Mr Chris Ntoumenopoulos have collectively committed a further $470,000 (subject to shareholder approval).

New funding will be deployed to fast-track TRP-8803 (IV-infused psilocin) clinical development into multiple, high value neuropsychiatric indications and advance TRP-8803's commercial readiness.

Management commentary

Chairman, Mr Herwig Janssen said: *"Investor support for this Placement, including strong participation from the Board and Tryp's co-founder, reflects a high level of confidence in the Company's strategy and growth trajectory. This additional funding will serve to accelerate the Company's clinical and commercial milestones, which includes key clinical and regulatory initiatives, while ensuring our interests remain closely aligned with shareholders."*

Chief Executive Officer, Jason Carroll, said: *"The funding marks an important step forward in advancing our clinical and operational roadmap for TRP-8803. With a robust balance sheet in place, the Company can now focus on accelerating our world first trial in Binge Eating Disorder with Swinburne University, fast tracking additional clinical trials into a broader range of high-value neuropsychiatric indications and progressing key initiatives for TRP-8803's commercial readiness including manufacturing and regulatory engagement."*

"On behalf of the Board and management, I would like to welcome new investors to the register and also thank existing shareholders for their ongoing support. Tryp has a number of initiatives pending which will allow the Company to maintain its strong operations momentum over the coming quarters and we look forward to providing

ongoing updates throughout the period ahead."

Placement details:

The Placement will be undertaken in a single tranche utilising the Company's existing capacity under Listing Rule 7.1. Director Placement Shares will be issued under Listing Rule 10.11 (including the proposed issue to Mr Herwig Janssen, Mr Jason Carroll, Mr Chris Ntoumenopoulos and Dr Daniel Tillett) subject to shareholder approval at an upcoming General Meeting. The issue price of $0.034 represents an 8.1% discount to the 15-day volume weighted average price (VWAP) of $0.037.

Taurus Capital Group acted as lead manager to the Placement and will receive a 6% fee on funds raised, as well as 20m options priced at $0.045 per option with a three-year expiry from date of issue (subject to shareholder approval). Director, Mr Chris Ntoumenopoulos has entered into a separate arrangement with the Company, whereby he will be paid a 6% fee on funds raised by him.

Indicative timetable:

Summary of key dates	Timing
ASX announcement of offer	Wednesday, 5 November 2025
Reinstatement to Official quotation	Wednesday, 5 November 2025
Settlement of Placement Shares	Monday, 17 November 2025
Allotment and trading of Placement Shares	Tuesday, 18 November 2025
General Meeting	TBA, estimated in January 2026
Settlement of Director Placement Shares	TBA, estimated in January 2026
Allotment and trading of Director Placement Shares	TBA, estimated in January 2026

The above timetable is indicative only and may change without notice.

This announcement has been authorised for release by the Board of Tryptamine Therapeutics Limited.

-ENDS-

Investor & media contact

Jason Carroll
Chief Executive Officer
Tryptamine Therapeutics Limited
jcarroll@tryptherapeutics.com

Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

About Tryptamine Therapeutics Limited

Tryp is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp's lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The Company has completed a Phase 2a clinical trial for the treatment of binge eating disorder at the University of Florida, which demonstrated an average reduction in binge eating episodes of greater than 80%.

For personal use only

The Company also has also just completed a Phase 2a clinical trial for the treatment of fibromyalgia in collaboration with the University of Michigan and has initiated a Phase 2a clinical trial in collaboration with Massachusetts General Hospital for the treatment of abdominal pain and visceral tenderness in patients suffering from irritable bowel syndrome.

Each of the studies is utilising TRP-8802 (synthetic, oral psilocybin) to demonstrate clinical benefit in these indications. Where a positive clinical response is demonstrated, subsequent studies are expected to utilise TRP-8803 (IV-infused psilocin), that has the potential to further improve efficacy, safety, and patient experience.

For more information, please visit www.tryptherapeutics.com.

Register for updates

The Company encourages investors to register their details with Automic Group investor portal. This also provides shareholders with the opportunity to elect communication methods to electronic only. This can be done by:

- *Go to investor.automic.com.au*
- *If you're an existing user, log in with your username and password*
- *If you're a new user, click 'register', select 'Tryptamine Therapeutics Limited'. Enter your Holding Number and postcode of the registered address on your holding. If your address is outside Australia, select the country. Follow the prompts to set up a username and password.*
- *Once you have created your account, you will need to update your communication method by clicking 'my details' under the 'profile' section of the investor portal account, then navigating to 'communication preferences' and select 'electronic only'*

Risks associated with Psilocin

All medicines carry risks and specialist prescribers, such as registered psychiatrists are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of psilocybin and similar compounds, such as psilocin, can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. These effects of psilocybin and its derivatives are unlikely at low doses and in the treatment regimens used in psychedelic-assisted psychotherapy and appropriately managed in a controlled environment with direct medical supervision.

Forward-Looking Information

Certain information in this news release, constitutes forward looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of Tryp's Replacement Prospectus available at www.asx.com.au These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

For personal use only